Filing Details

Accession Number:
0001127602-22-011526
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-04-05 16:08:15
Reporting Period:
2022-04-04
Accepted Time:
2022-04-05 16:08:15
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1492422 Apellis Pharmaceuticals Inc. APLS Pharmaceutical Preparations (2834) 271537290
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1651281 Lukas Scheibler C/O Apellis Pharmaceuticals, Inc.
100 Fifth Avenue, 3Rd Floor
Waltham MA 02451
Chief Innovation Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2022-04-04 3,504 $13.85 55,737 No 4 M Direct
Common Stock Disposition 2022-04-04 818 $55.84 54,919 No 4 S Direct
Common Stock Disposition 2022-04-04 1,437 $56.86 53,482 No 4 S Direct
Common Stock Disposition 2022-04-04 1,249 $57.81 52,233 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2022-04-04 3,504 $0.00 3,504 $13.85
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
50,000 2029-02-07 No 4 M Direct
Footnotes
  1. This is a scheduled exercise and sale from 10B5-1 trading plan.
  2. The sale price range within $1.00. Max. $55.21 - Min. $56.13
  3. The sale price range within $1.00. Max. $56.34 - Min. $57.22
  4. The sale price range within $1.00. Max. $57.37 - Min. $58.29.
  5. This represents a stock option grant made on 02/08/2019 that vests as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.